OPKO Health raises $125M in notes backed by mazdutide royalties
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/19/2026
- S&P 500, Nasdaq climb as AI-linked stocks recover ahead of earnings
- U.S. economy is "booming," JPMorgan’s Dimon says
- Musk pledges one share of SpaceX to every U.S. child
- Oil slips from five-month highs with Hormuz crossings, Russian sanctions waiver in focus
- Prepare to buy the dip as U.S. stock selloff nears its end: Morgan Stanley
- Brazil's Bolsonaro, Lula spar in first debate as personal attacks fly
- Cerebras Systems falls as TD Cowen cuts price target
- Glass House Brands posts Q3 revenue of $56.8M, board member exits
- S&P 500, Nasdaq climb as AI-linked stocks recover ahead of earnings
- Nvidia wins CPU business from Modal, previously exclusive to AMD and Intel
OPKO Health Expands Strategic Relationship with HealthCare Royalty Through $125 Million Notes Issuance Secured by Mazdutide Royalty Interests
August 13, 2026 9:15 AM EDTMIAMI, Fla., Aug. 13, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK)Â today announced the expansion of its financing relationship with HealthCare Royalty, a business of KKR (HCRx), through the issuance of an additional $125 million aggregate principal amount of senior secured notes. The newly issued notes are secured by OPKOs royalty interests arising under its mazdutide license agreement with Eli Lilly and Company and mature in 2044, consistent with the maturity of OPKOs existing HCRx notes issued under the original financing arrangement.
The transaction provides OPKO with additional... More



